PULSE Challenge: Brain delivery platform for large drug modalities
March 3, 2026 @ 15:00 – 16:00 CET
Brain uptake of therapeutic modalities such as antibodies, enzymes and other types of drug modalities is severely limited by their size due to the blood brain barrier (BBB). To address this issue, we have developed the BrainTransporterTM (BT) technology to actively transport these molecules across the BBB using receptor-mediated transcytosis. Our technology is engineered using structural data as guidance to engage with a BBB receptor at an optimal site.
Host: Per I Arvidsson
Moderator: Anna Ridderstad Wollberg
The seminar series PULSE Challenge is connected to the MSCA co-funded* postdoctoral program SciLifeLab PULSE, that will train 48 future leaders in life sciences. The program focuses on innovative, fundamental and translational research carried out in supportive and diverse academic and industrial environments, preparing postdocs with necessary skills for long-term career sustainability. Click HERE to find out more about SciLifeLab PULSE
On-line event via Zoom
Presenter:
Per-Ola Freskgård
Biography:
Per-Ola Freskgård is currently Chief Scientific Officer at BioArctic AB and a member of the Research & Development Leadership Team. Per-Ola previously served as vice Director & Distinguished Scientist within the Roche Neuroscience Discovery organization in Switzerland responsible for preclinical development of the Brain Shuttle delivery technology of biologics, which is now in clinical testing. Prior to that, he held a Section Head position in early and late discovery at AstraZeneca within the Neuroscience area and a member of the Technology Research Review Committee within the Medimmune and AstraZeneca organizations. Before joining AstraZeneca, Per-Ola served as Vice President and a member of the Executive Management Team at Nuevolution A/S and a co-inventor of the Chemetics technology. Prior to this, Per-Ola was a Project Manager at Maxygen responsible for research programs of antibody mimetics and a co-inventor of the Maxybody concept. Prior to that, Per-Ola was Head of the Discovery Research Department in the therapeutics division at Novo Nordisk A/S. Per-Ola conducted his post-doctoral fellowship in Professor Frances Arnold’s lab at the California Institute of Technology. He holds a Ph.D. in Protein Biochemistry from Linköping University, Sweden. Authored and co-authored more than 80 per-reviewed publications and patent applications
Google Calendar 
